IL153853A0 - Bifunctional molecules and vectors complexed therewith for targeted gene delivery - Google Patents

Bifunctional molecules and vectors complexed therewith for targeted gene delivery

Info

Publication number
IL153853A0
IL153853A0 IL15385301A IL15385301A IL153853A0 IL 153853 A0 IL153853 A0 IL 153853A0 IL 15385301 A IL15385301 A IL 15385301A IL 15385301 A IL15385301 A IL 15385301A IL 153853 A0 IL153853 A0 IL 153853A0
Authority
IL
Israel
Prior art keywords
gene delivery
targeted gene
bifunctional molecules
complexed therewith
vectors complexed
Prior art date
Application number
IL15385301A
Original Assignee
Novartis Ag
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Scripps Research Inst filed Critical Novartis Ag
Publication of IL153853A0 publication Critical patent/IL153853A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
IL15385301A 2000-07-10 2001-07-09 Bifunctional molecules and vectors complexed therewith for targeted gene delivery IL153853A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61301700A 2000-07-10 2000-07-10
PCT/EP2001/007878 WO2002004522A2 (en) 2000-07-10 2001-07-09 Bifunctional molecules and vectors complexed therewith for targeted gene delivery

Publications (1)

Publication Number Publication Date
IL153853A0 true IL153853A0 (en) 2003-07-31

Family

ID=24455529

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15385301A IL153853A0 (en) 2000-07-10 2001-07-09 Bifunctional molecules and vectors complexed therewith for targeted gene delivery

Country Status (6)

Country Link
EP (1) EP1301541A2 (en)
JP (1) JP2004502450A (en)
AU (1) AU2001277531A1 (en)
CA (1) CA2414272A1 (en)
IL (1) IL153853A0 (en)
WO (1) WO2002004522A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
IL165256A0 (en) 2002-05-24 2005-12-18 Schering Corp Neutralizing human anti-igfr antibody
CN1542132A (en) * 2003-04-30 2004-11-03 上海新霁生物科技有限公司 Highly expressed recombinant virus containing human constant region all-antibody gene and its use for treating tumor
JP2007510434A (en) 2003-11-12 2007-04-26 シェーリング　コーポレイション A plasmid system for multigene expression.
AR046639A1 (en) 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
ATE493442T1 (en) 2004-12-03 2011-01-15 Schering Corp BIOLOGICAL MARKERS FOR PRE-SELECTION OF PATIENTS FOR ANTI-IGF1R THERAPY
EP1885385A2 (en) * 2005-05-31 2008-02-13 THURNHER, Martin Andreas Phosphatidylinositol combination composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6685225B2 (en) * 2013-12-16 2020-04-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Depletion of plasmacytoid dendritic cells
EP3107563B1 (en) 2014-02-21 2021-04-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
BR112016022841B1 (en) 2014-04-03 2023-09-26 Igm Biosciences, Inc IGM, IGA, IGG/IGM OR IGG/IGA ANTIBODY COMPRISING A MODIFIED CHAIN
PL3247728T3 (en) 2015-01-20 2020-11-16 Igm Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN108463472A (en) 2015-09-30 2018-08-28 Igm生物科学有限公司 The binding molecule of J- chains with modification
CA2999284C (en) 2015-09-30 2023-06-13 Igm Biosciences A/S Binding molecules with modified j-chain
CL2016000164A1 (en) * 2016-01-21 2016-07-29 Pontificia Universidad Católica De Chile Monoclonal antibodies specific for the human adenovirus piii antigen (adv), produced and secreted by cellular hybridomas, useful for the detection and diagnosis of adv caused infection.
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742365B2 (en) * 1997-03-14 2002-01-03 Selective Genetics, Inc. Adenoviral vectors with modified tropism
DE19849643A1 (en) * 1998-10-29 2000-05-04 Deutsches Krebsforsch Antibodies to the AAV capsid that change cell tropism and method for directed gene transfer

Also Published As

Publication number Publication date
WO2002004522A3 (en) 2002-07-18
EP1301541A2 (en) 2003-04-16
JP2004502450A (en) 2004-01-29
WO2002004522A2 (en) 2002-01-17
CA2414272A1 (en) 2002-01-17
AU2001277531A1 (en) 2002-01-21

Similar Documents

Publication Publication Date Title
IL153853A0 (en) Bifunctional molecules and vectors complexed therewith for targeted gene delivery
MXPA02012749A (en) B7-like molecules and uses thereof.
HUP0202635A3 (en) Targeting multimeric imaging agents through multilocus binding
HK1053786A1 (en) Improved water-insoluble drug particle process
SI1248802T1 (en) Soluble ctla4 mutant molecules and uses thereof
AU5091201A (en) Vegf-modulated genes and methods employing them
AU7296801A (en) Il-17 molecules and uses thereof
AU4196801A (en) Chordin-like-2 molecules and uses thereof
EP1341497A4 (en) Receptor antagonist-lipid conjugates and delivery vehicles containing same
IL155139A0 (en) Targeting molecules for adenoviral vectors
EP1165597A4 (en) Bifunctional molecules for delivery of therapeutics
AU2088801A (en) Metastasis genes and uses thereof
AU4744201A (en) Systemic gene delivery vehicles for the treatment of tumors
EP1147213A4 (en) Novel rgs-containing molecules and uses thereof
IL128193A0 (en) Rhamnosyl-transferase gene and uses thereof
AU2002356898A8 (en) Gene amplification and overexpression in cancer
AU2002365188A8 (en) Nucleic acid delivery and expression
AU2001262974A1 (en) Dna alkylating agent and activation thereof
IL153573A0 (en) Clk-2, cek-7 and coq-4 genes, and uses thereof
IL145775A0 (en) 13 transmembrane protein expressed in prostate cancer
EP1173192A4 (en) Methods and compositions for targeted drug delivery
GB0107560D0 (en) Improvements in travelling wave amplifiers
AU8229901A (en) Genes and proteins, and their uses
EP1229924A4 (en) Targeted bifunctional molecules and therapies based thereon
GB0008966D0 (en) Vectors for gene therapy